LCM
BBIO icon

Laurion Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Laurion Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101M Buy
1,352,234
+89,583
+7% +$6.27M 2.58% 6
2026
Q1 		$93.8M Sell
1,262,651
-139,499
-10% -$10.1M 4.09% 3
2025
Q4 		$107M Sell
1,402,150
-351,394
-20% -$23.1M 3.99% 3
2025
Q3 		$91.1M Sell
1,753,544
-657,704
-27% -$32.1M 1.57% 16
2025
Q2 		$104M Sell
2,411,248
-566,919
-19% -$20.6M 1.88% 13
2025
Q1 		$103M Sell
2,978,167
-762,729
-20% -$25.7M 2.59% 9
2024
Q4 		$103M Sell
3,740,896
-153,386
-4% -$3.96M 1.88% 15
2024
Q3 		$99.1M Sell
3,894,282
-494,591
-11% -$13M 1.35% 18
2024
Q2 		$111M Sell
4,388,873
-787,455
-15% -$21.5M 1.32% 22
2024
Q1 		$160M Sell
5,176,328
-65,505
-1% -$2.23M 1.36% 11
2023
Q4 		$212M Sell
5,241,833
-409,206
-7% -$12.3M 1.79% 10
2023
Q3 		$149M Buy
5,651,039
+901,696
+19% +$25.6M 0.91% 31
2023
Q2 		$81.7M Buy
4,749,343
+1,236,584
+35% +$18.6M 0.46% 44
2023
Q1 		$58.2M Buy
3,512,759
+1,289,505
+58% +$15M 0.4% 63
2022
Q4 		$16.9M Buy
2,223,254
+198,614
+10% +$1.9M 0.08% 183
2022
Q3 		$20.1M Buy
2,024,640
+550,190
+37% +$5.72M 0.12% 138
2022
Q2 		$13.4M Buy
1,474,450
+778,535
+112% +$6.51M 0.21% 96
2022
Q1 		$7.06M Buy
+695,915
New +$7.14M 0.09% 139
2019
Q4 		– Sell
-11,200
Closed -$240K – 898
2019
Q3 		$240K Sell
11,200
-13,800
-55% -$382K ﹤0.01% 902
2019
Q2 		$674K Buy
+25,000
New +$682K 0.01% 637

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Laurion Capital Management's BBIO Position: Q2 2026 in Review

Laurion Capital Management increased its BridgeBio Pharma (BBIO) stake by 7.1% in Q2 2026, buying an estimated $6.27M and bringing the position to 1,352,234 shares worth $101M. The position accounts for 2.58% of the portfolio, ranked #6.

Laurion Capital Management first reported a position in BBIO in Q2 2019 and has held it in 20 quarters since. The position peaked at $212M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Laurion Capital Management held 1,352,234 shares of BridgeBio Pharma worth $101M as of Q2 2026.
  • Laurion Capital Management bought 89,583 BridgeBio Pharma shares in Q2 2026, an estimated $6.27M.
  • BridgeBio Pharma made up 2.58% of Laurion Capital Management's portfolio in Q2 2026, its #6 holding.
  • Laurion Capital Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 20 quarters since.
  • Laurion Capital Management's BridgeBio Pharma position peaked at $212M in Q4 2023.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.